Enzychem Lifesciences
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Enzychem Lifesciences is a South Korean biopharmaceutical and specialty-chemicals company listed on KOSDAQ, the country's tech and small-cap exchange.
It develops prescription medicines for conditions such as oral mucositis caused by cancer treatment, acute radiation syndrome, and atopic dermatitis, while also supplying active pharmaceutical ingredients used in drug manufacturing and MRI contrast agents. Its business spans four segments: novel drug development, active pharmaceutical ingredients, health-supplement foods, and a subsidiary that supplies bio-based oils used as feedstocks for sustainable aviation fuel.
Summary is AI-generated and may contain errors · figures from DART filings
Its subsidiary Shinheung Mulsan operates the bio-oil feedstock segment, making the company's revenue base broader than its drug-development pipeline alone.
Enzychem Lifesciences in five facts
What does Enzychem Lifesciences do?
Enzychem Lifesciences is a South Korean biopharmaceutical and specialty-chemicals company listed on KOSDAQ, the country's tech and small-cap exchange.
Where is Enzychem Lifesciences listed and in which sector?
Enzychem Lifesciences (Korean name: 엔지켐생명과학) trades under KRX code 183490 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Enzychem Lifesciences?
Its market capitalisation was US$63.2M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Enzychem Lifesciences's latest annual revenue and operating profit?
For fiscal year 2025, Enzychem Lifesciences reported revenue of US$51.1M, an operating loss of US$10.8M and a net loss of US$13.7M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was down 12.4% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on large shareholdings (5% rule) (standard)Oct 15
- DisclosureSep 11
- [Amended] Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Enzychem Lifesciences updated its previously filed consolidated results for FY2025: revenue of US$45.6M (−12.44% year on year), an operating loss of US$9.66M and a net loss of US$12.2M.
Earnings · Mar 18 · 2 versions - Treasury share disposal: results reportTreasury Shares · Feb 27
- Treasury share disposal: results reportTreasury Shares · Feb 27
- [Amended] Material event report (treasury share disposal)
Enzychem Lifesciences updated a disclosed plan to sell treasury shares worth US$2.46M, about 4.2% of its market value.
Treasury Shares · Feb 25 · 3 versions - Material event report (treasury share disposal)
Enzychem Lifesciences disclosed a plan to sell treasury shares worth US$5.56M, about 9.6% of its market value.
Treasury Shares · Feb 20